Life Care Ctr Of Lawrenceville | |
210 Collins Industrial Way, Lawrenceville, Georgia 30045 | |
(678) 442-0777 | |
Name | Life Care Ctr Of Lawrenceville |
---|---|
Location | 210 Collins Industrial Way, Lawrenceville, Georgia |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 125 |
Occupancy Rate | 52.56% |
Medicare ID (CCN) | 115659 |
Legal Business Name | Gwinnett Operations Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1356374011 |
Organization Name | GWINNETT OPERATIONS, LLC |
Doing Business As | LIFE CARE CENTER OF LAWRENCEVILLE |
Address | 210 Collins Industrial Way, Lawrenceville, GA 30043 |
Phone Number | 678-442-0777 |
News Archive
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
The latest report from the Australian Institute of Health and Welfare (AIHW) says between 2006 and 2007 more than a million hospital admissions in Australia were due to chronic kidney disease which was also a contributing factor in one in 10 deaths in 2006.
Research is underway at Rochester Institute of Technology that will give scientists a better understanding of the vitreous humor, or gel, that fills the eye and could lead to advances in the treatment of vision disorders, drug delivery and eye surgery.
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
The latest report from the Australian Institute of Health and Welfare (AIHW) says between 2006 and 2007 more than a million hospital admissions in Australia were due to chronic kidney disease which was also a contributing factor in one in 10 deaths in 2006.
Research is underway at Rochester Institute of Technology that will give scientists a better understanding of the vitreous humor, or gel, that fills the eye and could lead to advances in the treatment of vision disorders, drug delivery and eye surgery.
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 22.22 | 14.46 |
Percentage of long-stay residents who lose too much weight | 6.67 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 45.28 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.38 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.67 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.97 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.14 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 16.15 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.62 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 37.44 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.01 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 9.16 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 54.22 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.26 | 82.93 |
News Archive
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
The latest report from the Australian Institute of Health and Welfare (AIHW) says between 2006 and 2007 more than a million hospital admissions in Australia were due to chronic kidney disease which was also a contributing factor in one in 10 deaths in 2006.
Research is underway at Rochester Institute of Technology that will give scientists a better understanding of the vitreous humor, or gel, that fills the eye and could lead to advances in the treatment of vision disorders, drug delivery and eye surgery.
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.
› Verified 4 days ago
Life Care Center Of Gwinnett Location: 3850 Safehaven Drive, Lawrenceville, Georgia 30044 Phone: (770) 923-0005 | |
Delmar Gardens Of Gwinnett Location: 3100 Club Drive, Lawrenceville, Georgia 30044 Phone: (770) 923-3100 | |
Northside Gwinnett Extended Care Center Location: 650 Professional Drive, Lawrenceville, Georgia 30046 Phone: (678) 312-3000 | |
Life Care Ctr Of Lawrenceville Location: 210 Collins Industrial Way, Lawrenceville, Georgia 30045 Phone: (678) 442-0777 | |
Mesun Health And Rehabilitation Center Location: 88 Johnson Road, Building #2, Lawrenceville, Georgia 30046 Phone: (404) 367-1907 |